April 24th 2024
During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Kirtland Discusses the American Cancer Society's Report on Significant Drop in Lung Cancer Deaths
January 18th 2020In an interview with Targeted Oncology, Steven H. Kirtland, MD, FCCP, discussed the different factors that play a role in the decline of lung cancer mortality over the last few years. He highlighted how these advancements will continue to impact the survival of patients with lung cancer and his thoughts on the evolving landscape.
Read More
Integrating a geriatric assessment into the care of older adults who are receiving cancer treatment in communi­ty oncology practices improves patient and caregiver satisfaction and encourages commu­nication about aging-related concerns, accord­ing to results of a clinical trial that enrolled 541 patients with advanced cancer.
Read More
Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers
January 18th 2020In an interview with Targeted Oncology, Pasi A. Jänne, MD, PhD, discussed the current treatment landscape for patients with EGFR-mutant lung cancer, as well as some therapies that currently are under both preclinical and clinical investigation at the Dana-Farber Cancer Institute. He shared advice for community oncologists treating this patient population.
Read More
FDA Priority Review Granted To Nivolumab/Ipilimumab for Treatment of Advanced NSCLC
January 16th 2020The FDA has granted priority review to the Biologics License Application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations, according to a press release from the Bristol-Myers Squibb Company.<br />
Read More
Telehealth Delivers Access to Care and Cutting-Edge Clinical Research to Rural Areas
January 11th 2020The present and future benefits of telehealth in oncology can be observed through Tahoe For­est Cancer Center and its affiliation with the UC Davis Cancer Center, use of other remote clinics, and participation in virtual tumor boards. Even though there are roadblocks to telehealth reaching more locations and more patients, the potential benefit warrants the time needed to get over those hurdles.
Read More
Pembrolizumab Plus Chemotherapy Phase III Study Shows Mixed Results in SCLC
January 9th 2020The combination of pembrolizumab and chemotherapy improved progression-free survival in patients with small cell lung cancer compared with chemotherapy alone, meeting 1 of the primary end points of the phase III KEYNOTE-604 study, according to a press release from pembrolizumab developer, Merck. Compared with a chemotherapy regimen of either etoposide plus cisplatin or cisplatin alone, the progression-free survival mprovement with pembrolizumab was significant.
Read More
Experts Reflect on the Most Impactful FDA Moves of 2019
January 4th 2020The FDA granted approval to countless treatments across cancer types throughout 2019 until the end of the year, with a final approval on December 31<sup>st </sup>for the first BRCA targeted therapy in pancreatic cancer. Following the excitement for a new year of further advances, Targeted Oncology followers on Twitter shared their thoughts on some of the most impactful FDA approvals in 2019.
Read More
A Look Back at FDA News from December 2019
January 2nd 2020In December 2019, the FDA approved a number of new treatments in lung cancer, pancreatic cancer, urothelial carcinoma, breast cancer, and prostate cancer. A tissue complete assay was also approved by the FDA for use in a clinical trial evaluating pembrolizumab.
Read More
Osimertinib Shows Antitumor Activity in NSCLC Harboring Uncommon EGFR Mutations
December 31st 2019Osimertinib demonstrated a manageable toxicity profile and encouraging activity in patients with non–small cell lung cancer who harbor an uncommon EGFR mutation, according to results from a phase II clinical trial conducted in Korea.
Read More
First Randomized Phase III Trial Opens for Treatment-Naive RET Fusion-Positive NSCLC
December 28th 2019Selpercatinib will be compared with the standard of care in the first ever phase III clinical trial in patients with advanced or metastatic treatment-naïve <em>RET</em> fusion-positive non–small cell lung cancer, according to a press release from Eli Lilly and Company.
Read More
Regulatory Approval Moves Ahead for Lurbinectedin in SCLC
December 19th 2019A new drug application has been filed for accelerated approval with the FDA for lurbinectedin in patients with small cell lung cancer who have progressed after prior platinum-containing therapy, according to the manufacturer, PharmaMar.1 The filing was based on results from a phase II basket trial, presented at the 2019 ASCO Annual Meeting.
Read More
Pembrolizumab Boosts Survival in Metastatic Nonsquamous NSCLC Regardless of KRAS Mutations
December 16th 2019Pembrolizumab showed improvements in overall survival, progression-free survival, and objective response rate compared with pemetrexed or paclitaxel chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer whose tumors are PD-L1–positive, regardless of their KRAS mutational status.
Read More
EGFR TKI Resistance Identified in a Patient with EGFR- and BRAF-Mutant Lung Adenocarcinoma
December 14th 2019In an interview with Targeted Oncology, Brennan J. Decker, MD, PhD, discussed a real-life scenario of a patient with lung cancer who harbored both an EGFR and BRAF mutation. He highlighted the key takeaways of this case, which he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo.
Read More
Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC
December 13th 2019With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non–small cell lung cancer, novel options like lazertinib, an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib has shown promise for the treatment of this patient population, according to a phase I/II dose-escalation study published in The Lancet Oncology.
Read More
Pennell Treats a Patient With NSCLC and a Genetic Mutation
December 13th 2019In a Targeted Oncology case-based peer perspectives live discussion, Nathan A. Pennell, MD, PhD, associate professor of the Department of Medicine at Case Western Reserve University and a medical oncologist at Taussig Cancer Center and the Cleveland Clinic Cancer Center discussed treatment options for EGFR-mutant non–small cell lung cancer, based on the case of a real patient.<br />
Read More
Oligometastatic Lung Cancer: How Should It Be Managed?
December 12th 2019Cancer has historically been divided between localized and metastatic disease. The underlying principle, derived from the Halsted theory of cancer progression, is that once cancer has spread to other sites, it is a systemic disease. Heroic efforts to remove or ablate all evidence of visible cancer thus would expose patients to toxicity without a chance for benefit.
Read More
Identification of EGFR Mutations Impacts Overall Prognosis in Lung Cancers
December 7th 2019Brennan J. Decker, MD, PhD, discusses the role of identifying <em>EGFR</em> mutations in patients with lung cancers. In lung adenocarcinoma, there are many different activating mutations that can lead to the development of cancer, Decker explains.
Watch
Elio Tissue Complete Assay Approved by FDA for Use in a Pembrolizumab-Based Trial
December 5th 2019The FDA granted an Investigational Device Exemption approval to the Personal Genome Diagnostics Inc. elio<sup>TM</sup> tissue complete assay for use in a Merck trial evaluating pembrolizumab combinations in non–small cell lung cancer, according to a press release from PGDx, developer of the assay.
Read More
FLAURA Trial Update: Osimertinib Outperforms Other TKIs for OS in Advanced NSCLC
December 5th 2019New results from the FLAURA trial have shown that patients with treatment-naïve, EGFR mutation–positive advanced non–small-cell lung cancer who received first-line osimertinib experienced improved overall survival compared with patients who received either gefitinib or erlotinib.
Read More
FDA Approves Atezolizumab Plus Chemotherapy for Treatment of Patients With mNSCLC
December 4th 2019The FDA has approved the combination of atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy for the treatment of patients with metastatic nonsquamous non–small cell lung cancer, according to a press release from Genentech USA, Inc.<br />
Read More
Enhancing Benefit With Durvalumab in NSCLC After the PACIFIC Trial
December 3rd 2019Andreas Rimner, MD, gives an overview of his presentation titled, “Crossing the PACIFIC,” which he presented at the 2019 New York Lung Cancers Symposium. He evaluates some potential next steps for durvalumab (Imfinzi) following the practice-changing results from the PACIFIC trial.
Watch
Durvalumab sBLA Granted Priority Review by the FDA
November 30th 2019A supplemental Biologics License Application for durvalumab has been accepted by the FDA, and the drug has been granted priority review for the treatment of previously untreated extensive-stage small cell lung cancer, according to a press release from AstraZeneca.
Read More